Overview

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Status:
Not yet recruiting

Trial end date:
2024-10-23

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).

Phase:

Early Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Caffeine
Caffeine citrate
Metoprolol
Midazolam
Omeprazole
Vitamin K
Warfarin